There were 519 press releases posted in the last 24 hours and 166,620 in the last 365 days.

Global Neurodegenerative Drugs Industry

Neurodegenerative Drugs market worldwide is projected to grow by US$15. 5 Billion, driven by a compounded growth of 5. 8%. Parkinson’s Disease, one of the segments analyzed and sized in this study, displays the potential to grow at over 6.

/EIN News/ -- New York, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neurodegenerative Drugs Industry" - https://www.reportlinker.com/p05818013/?utm_source=GNW
4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$15.3 Billion by the year 2025, Parkinson’s Disease will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 4.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$546.7 Million to the region’s size and clout in the next 5 to 6 years. Over US$472.9 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Parkinson’s Disease will reach a market size of US$760.5 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 8.5% over the next couple of years and add approximately US$4.2 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, Biogen, Inc.; Boehringer Ingelheim GmbH; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; H. Lundbeck A/S; Merck KGaA; Mitsubishi Tanabe Pharma Corporation; Novartis International AG; Pfizer, Inc.; Reata Pharmaceuticals, Inc.; Sage Therapeutics, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.; UCB SA


Read the full report: https://www.reportlinker.com/p05818013/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Neurodegenerative Drugs Competitor Market Share Scenario
Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: Neurodegenerative Drugs Global Market Estimates and
Forecasts in US$ Million by Region/Country: 2018-2025
Table 2: Neurodegenerative Drugs Global Retrospective Market
Scenario in US$ Million by Region/Country: 2009-2017
Table 3: Neurodegenerative Drugs Market Share Shift across Key
Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: Parkinson?s Disease (Indication Drug) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 5: Parkinson?s Disease (Indication Drug) Historic Market
Analysis by Region/Country in US$ Million: 2009 to 2017
Table 6: Parkinson?s Disease (Indication Drug) Market Share
Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS
2025
Table 7: Huntington Disease (Indication Drug) Potential Growth
Markets Worldwide in US$ Million: 2018 to 2025
Table 8: Huntington Disease (Indication Drug) Historic Market
Perspective by Region/Country in US$ Million: 2009 to 2017
Table 9: Huntington Disease (Indication Drug) Market Sales
Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
Table 10: Amyotrophic Lateral Sclerosis (Indication Drug)
Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
Table 11: Amyotrophic Lateral Sclerosis (Indication Drug)
Region Wise Breakdown of Global Historic Demand in US$ Million:
2009 to 2017
Table 12: Amyotrophic Lateral Sclerosis (Indication Drug)
Market Share Distribution in Percentage by Region/Country: 2009
VS 2019 VS 2025
Table 13: Alzheimer?s Disease (Indication Drug) World Market
Estimates and Forecasts by Region/Country in US$ Million: 2018
to 2025
Table 14: Alzheimer?s Disease (Indication Drug) Market Historic
Review by Region/Country in US$ Million: 2009 to 2017
Table 15: Alzheimer?s Disease (Indication Drug) Market Share
Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Other Indication Drugs (Indication Drug) World Market
by Region/Country in US$ Million: 2018 to 2025
Table 17: Other Indication Drugs (Indication Drug) Historic
Market Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Other Indication Drugs (Indication Drug) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Neurodegenerative Drugs Market Share (in %) by Company: 2019 &
2025
Table 19: United States Neurodegenerative Drugs Market
Estimates and Projections in US$ Million by Indication Drug:
2018 to 2025
Table 20: Neurodegenerative Drugs Market in the United States
by Indication Drug: A Historic Review in US$ Million for
2009-2017
Table 21: United States Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
CANADA
Table 22: Canadian Neurodegenerative Drugs Market Estimates and
Forecasts in US$ Million by Indication Drug: 2018 to 2025
Table 23: Canadian Neurodegenerative Drugs Historic Market
Review by Indication Drug in US$ Million: 2009-2017
Table 24: Neurodegenerative Drugs Market in Canada: Percentage
Share Breakdown of Sales by Indication Drug for 2009, 2019, and
2025
JAPAN
Table 25: Japanese Market for Neurodegenerative Drugs: Annual
Sales Estimates and Projections in US$ Million by Indication
Drug for the Period 2018-2025
Table 26: Neurodegenerative Drugs Market in Japan: Historic
Sales Analysis in US$ Million by Indication Drug for the Period
2009-2017
Table 27: Japanese Neurodegenerative Drugs Market Share
Analysis by Indication Drug: 2009 VS 2019 VS 2025
CHINA
Table 28: Chinese Neurodegenerative Drugs Market Growth
Prospects in US$ Million by Indication Drug for the Period
2018-2025
Table 29: Neurodegenerative Drugs Historic Market Analysis in
China in US$ Million by Indication Drug: 2009-2017
Table 30: Chinese Neurodegenerative Drugs Market by Indication
Drug: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European Neurodegenerative Drugs Market: Competitor Market
Share Scenario (in %) for 2019 & 2025
Table 31: European Neurodegenerative Drugs Market Demand
Scenario in US$ Million by Region/Country: 2018-2025
Table 32: Neurodegenerative Drugs Market in Europe: A Historic
Market Perspective in US$ Million by Region/Country for the
Period 2009-2017
Table 33: European Neurodegenerative Drugs Market Share Shift
by Region/Country: 2009 VS 2019 VS 2025
Table 34: European Neurodegenerative Drugs Market Estimates and
Forecasts in US$ Million by Indication Drug: 2018-2025
Table 35: Neurodegenerative Drugs Market in Europe in US$
Million by Indication Drug: A Historic Review for the Period
2009-2017
Table 36: European Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
FRANCE
Table 37: Neurodegenerative Drugs Market in France by
Indication Drug: Estimates and Projections in US$ Million for
the Period 2018-2025
Table 38: French Neurodegenerative Drugs Historic Market
Scenario in US$ Million by Indication Drug: 2009-2017
Table 39: French Neurodegenerative Drugs Market Share Analysis
by Indication Drug: 2009 VS 2019 VS 2025
GERMANY
Table 40: Neurodegenerative Drugs Market in Germany: Recent
Past, Current and Future Analysis in US$ Million by Indication
Drug for the Period 2018-2025
Table 41: German Neurodegenerative Drugs Historic Market
Analysis in US$ Million by Indication Drug: 2009-2017
Table 42: German Neurodegenerative Drugs Market Share Breakdown
by Indication Drug: 2009 VS 2019 VS 2025
ITALY
Table 43: Italian Neurodegenerative Drugs Market Growth
Prospects in US$ Million by Indication Drug for the Period
2018-2025
Table 44: Neurodegenerative Drugs Historic Market Analysis in
Italy in US$ Million by Indication Drug: 2009-2017
Table 45: Italian Neurodegenerative Drugs Market by Indication
Drug: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
Table 46: United Kingdom Market for Neurodegenerative Drugs:
Annual Sales Estimates and Projections in US$ Million by
Indication Drug for the Period 2018-2025
Table 47: Neurodegenerative Drugs Market in the United Kingdom:
Historic Sales Analysis in US$ Million by Indication Drug for
the Period 2009-2017
Table 48: United Kingdom Neurodegenerative Drugs Market Share
Analysis by Indication Drug: 2009 VS 2019 VS 2025
SPAIN
Table 49: Spanish Neurodegenerative Drugs Market Estimates and
Forecasts in US$ Million by Indication Drug: 2018 to 2025
Table 50: Spanish Neurodegenerative Drugs Historic Market
Review by Indication Drug in US$ Million: 2009-2017
Table 51: Neurodegenerative Drugs Market in Spain: Percentage
Share Breakdown of Sales by Indication Drug for 2009, 2019, and
2025
RUSSIA
Table 52: Russian Neurodegenerative Drugs Market Estimates and
Projections in US$ Million by Indication Drug: 2018 to 2025
Table 53: Neurodegenerative Drugs Market in Russia by
Indication Drug: A Historic Review in US$ Million for 2009-2017
Table 54: Russian Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 55: Rest of Europe Neurodegenerative Drugs Market
Estimates and Forecasts in US$ Million by Indication Drug:
2018-2025
Table 56: Neurodegenerative Drugs Market in Rest of Europe in
US$ Million by Indication Drug: A Historic Review for the
Period 2009-2017
Table 57: Rest of Europe Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 58: Asia-Pacific Neurodegenerative Drugs Market Estimates
and Forecasts in US$ Million by Region/Country: 2018-2025
Table 59: Neurodegenerative Drugs Market in Asia-Pacific:
Historic Market Analysis in US$ Million by Region/Country for
the Period 2009-2017
Table 60: Asia-Pacific Neurodegenerative Drugs Market Share
Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 61: Neurodegenerative Drugs Market in Asia-Pacific by
Indication Drug: Estimates and Projections in US$ Million for
the Period 2018-2025
Table 62: Asia-Pacific Neurodegenerative Drugs Historic Market
Scenario in US$ Million by Indication Drug: 2009-2017
Table 63: Asia-Pacific Neurodegenerative Drugs Market Share
Analysis by Indication Drug: 2009 VS 2019 VS 2025
AUSTRALIA
Table 64: Neurodegenerative Drugs Market in Australia: Recent
Past, Current and Future Analysis in US$ Million by Indication
Drug for the Period 2018-2025
Table 65: Australian Neurodegenerative Drugs Historic Market
Analysis in US$ Million by Indication Drug: 2009-2017
Table 66: Australian Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
INDIA
Table 67: Indian Neurodegenerative Drugs Market Estimates and
Forecasts in US$ Million by Indication Drug: 2018 to 2025
Table 68: Indian Neurodegenerative Drugs Historic Market Review
by Indication Drug in US$ Million: 2009-2017
Table 69: Neurodegenerative Drugs Market in India: Percentage
Share Breakdown of Sales by Indication Drug for 2009, 2019, and
2025
SOUTH KOREA
Table 70: Neurodegenerative Drugs Market in South Korea: Recent
Past, Current and Future Analysis in US$ Million by Indication
Drug for the Period 2018-2025
Table 71: South Korean Neurodegenerative Drugs Historic Market
Analysis in US$ Million by Indication Drug: 2009-2017
Table 72: Neurodegenerative Drugs Market Share Distribution in
South Korea by Indication Drug: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
Table 73: Rest of Asia-Pacific Market for Neurodegenerative
Drugs: Annual Sales Estimates and Projections in US$ Million by
Indication Drug for the Period 2018-2025
Table 74: Neurodegenerative Drugs Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Million by
Indication Drug for the Period 2009-2017
Table 75: Rest of Asia-Pacific Neurodegenerative Drugs Market
Share Analysis by Indication Drug: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 76: Latin American Neurodegenerative Drugs Market Trends
by Region/Country in US$ Million: 2018-2025
Table 77: Neurodegenerative Drugs Market in Latin America in
US$ Million by Region/Country: A Historic Perspective for the
Period 2009-2017
Table 78: Latin American Neurodegenerative Drugs Market
Percentage Breakdown of Sales by Region/Country: 2009, 2019,
and 2025
Table 79: Latin American Neurodegenerative Drugs Market Growth
Prospects in US$ Million by Indication Drug for the Period
2018-2025
Table 80: Neurodegenerative Drugs Historic Market Analysis in
Latin America in US$ Million by Indication Drug: 2009-2017
Table 81: Latin American Neurodegenerative Drugs Market by
Indication Drug: Percentage Breakdown of Sales for 2009, 2019,
and 2025
ARGENTINA
Table 82: Argentinean Neurodegenerative Drugs Market Estimates
and Forecasts in US$ Million by Indication Drug: 2018-2025
Table 83: Neurodegenerative Drugs Market in Argentina in US$
Million by Indication Drug: A Historic Review for the Period
2009-2017
Table 84: Argentinean Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
BRAZIL
Table 85: Neurodegenerative Drugs Market in Brazil by
Indication Drug: Estimates and Projections in US$ Million for
the Period 2018-2025
Table 86: Brazilian Neurodegenerative Drugs Historic Market
Scenario in US$ Million by Indication Drug: 2009-2017
Table 87: Brazilian Neurodegenerative Drugs Market Share
Analysis by Indication Drug: 2009 VS 2019 VS 2025
MEXICO
Table 88: Neurodegenerative Drugs Market in Mexico: Recent
Past, Current and Future Analysis in US$ Million by Indication
Drug for the Period 2018-2025
Table 89: Mexican Neurodegenerative Drugs Historic Market
Analysis in US$ Million by Indication Drug: 2009-2017
Table 90: Mexican Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 91: Rest of Latin America Neurodegenerative Drugs Market
Estimates and Projections in US$ Million by Indication Drug:
2018 to 2025
Table 92: Neurodegenerative Drugs Market in Rest of Latin
America by Indication Drug: A Historic Review in US$ Million
for 2009-2017
Table 93: Rest of Latin America Neurodegenerative Drugs Market
Share Breakdown by Indication Drug: 2009 VS 2019 VS 2025
MIDDLE EAST
Table 94: The Middle East Neurodegenerative Drugs Market
Estimates and Forecasts in US$ Million by Region/Country:
2018-2025
Table 95: Neurodegenerative Drugs Market in the Middle East by
Region/Country in US$ Million: 2009-2017
Table 96: The Middle East Neurodegenerative Drugs Market Share
Breakdown by Region/Country: 2009, 2019, and 2025
Table 97: The Middle East Neurodegenerative Drugs Market
Estimates and Forecasts in US$ Million by Indication Drug: 2018
to 2025
Table 98: The Middle East Neurodegenerative Drugs Historic
Market by Indication Drug in US$ Million: 2009-2017
Table 99: Neurodegenerative Drugs Market in the Middle East:
Percentage Share Breakdown of Sales by Indication Drug for
2009, 2019, and 2025
IRAN
Table 100: Iranian Market for Neurodegenerative Drugs: Annual
Sales Estimates and Projections in US$ Million by Indication
Drug for the Period 2018-2025
Table 101: Neurodegenerative Drugs Market in Iran: Historic
Sales Analysis in US$ Million by Indication Drug for the Period
2009-2017
Table 102: Iranian Neurodegenerative Drugs Market Share
Analysis by Indication Drug: 2009 VS 2019 VS 2025
ISRAEL
Table 103: Israeli Neurodegenerative Drugs Market Estimates and
Forecasts in US$ Million by Indication Drug: 2018-2025
Table 104: Neurodegenerative Drugs Market in Israel in US$
Million by Indication Drug: A Historic Review for the Period
2009-2017
Table 105: Israeli Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 106: Saudi Arabian Neurodegenerative Drugs Market Growth
Prospects in US$ Million by Indication Drug for the Period
2018-2025
Table 107: Neurodegenerative Drugs Historic Market Analysis in
Saudi Arabia in US$ Million by Indication Drug: 2009-2017
Table 108: Saudi Arabian Neurodegenerative Drugs Market by
Indication Drug: Percentage Breakdown of Sales for 2009, 2019,
and 2025
UNITED ARAB EMIRATES
Table 109: Neurodegenerative Drugs Market in the United Arab
Emirates: Recent Past, Current and Future Analysis in US$
Million by Indication Drug for the Period 2018-2025
Table 110: United Arab Emirates Neurodegenerative Drugs
Historic Market Analysis in US$ Million by Indication Drug:
2009-2017
Table 111: Neurodegenerative Drugs Market Share Distribution in
United Arab Emirates by Indication Drug: 2009 VS 2019 VS 2025
REST OF MIDDLE EAST
Table 112: Neurodegenerative Drugs Market in Rest of Middle
East: Recent Past, Current and Future Analysis in US$ Million
by Indication Drug for the Period 2018-2025
Table 113: Rest of Middle East Neurodegenerative Drugs Historic
Market Analysis in US$ Million by Indication Drug: 2009-2017
Table 114: Rest of Middle East Neurodegenerative Drugs Market
Share Breakdown by Indication Drug: 2009 VS 2019 VS 2025
AFRICA
Table 115: African Neurodegenerative Drugs Market Estimates and
Projections in US$ Million by Indication Drug: 2018 to 2025
Table 116: Neurodegenerative Drugs Market in Africa by
Indication Drug: A Historic Review in US$ Million for 2009-2017
Table 117: African Neurodegenerative Drugs Market Share
Breakdown by Indication Drug: 2009 VS 2019 VS 2025

IV. COMPETITION

BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DAIICHI SANKYO
EISAI CO.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
H. LUNDBECK A/S
MERCK KGAA
MITSUBISHI TANABE PHARMA CORPORATION
NOVARTIS INTERNATIONAL AG
PFIZER
REATA PHARMACEUTICALS
SAGE THERAPEUTICS, INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES
UCB SA

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05818013/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
Distribution channels: Media, Advertising & PR


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.